Press Releases Items Per Page 102550 Year None2018201720162015201420132012201120102007 01.08.15 Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea 07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models 06.30.14 First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax's Entinostat 05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting 03.28.14 Syndax Files Registration Statement for Proposed Initial Public Offering 03.20.14 ECOG-ACRIN Opens Phase III Trial of Syndax?s Entinostat in Advanced Breast Cancer 02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer 02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director 01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee 11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer 09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer 09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 Next page next › Last page last »
01.08.15 Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea
07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models
05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting
02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer
02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director
01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee
11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer
09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
